Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News
SuperBuzz: Die KI-Aktie, die man sich jetzt zum Ende des Sommers nicht entgehen lassen darf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DHX9 | ISIN: DK0061802139 | Ticker-Symbol: 4AJ0
Tradegate
29.08.25 | 20:59
26,800 Euro
-0,59 % -0,160
Branche
Pharma
Aktienmarkt
STOXX Europe 600
1-Jahres-Chart
ALK-ABELLO A/S Chart 1 Jahr
5-Tage-Chart
ALK-ABELLO A/S 5-Tage-Chart
RealtimeGeldBriefZeit
26,82027,10030.08.
26,82027,10029.08.

Aktuelle News zur ALK-ABELLO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.08.ALK-Abelló Earnings Rise In Q2; Stock Gains3
ALK-ABELLO Aktie jetzt für 0€ handeln
21.08.ALK-Abelló A/S gives Q2 results2
21.08.ALK Abello: Six-month interim report (Q2) 2025 (unaudited)102ALK delivers 12% organic revenue growth with operating profit up 41% in Q2 Q2 results exceeded expectations, driven by an improved momentum for tablets and adrenaline autoinjectors. Sales in Europe...
► Artikel lesen
14.08.ALK Abello: Invitation to the presentation of ALK's first six months (Q2) 2025 results on Thursday, 21 August 20251
12.08.ALK Abello: ALK upgrades its full-year revenue outlook141Inside information ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded. Revenue is now expected to grow by 12-14% in local currencies (previously...
► Artikel lesen
21.07.ALK Abello: ALK's tree pollen tablet (ITULAZAX) now recommended by NICE for use in the UK health system1
18.07.ALK Abello: EURneffy approved as the first needle-free anaphylaxis treatment of adults and children in the UK369Inside Information ALK (ALKB:DC / OMX: ALK B) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved EURneffy® 2 mg in the United Kingdom (UK) for anaphylaxis...
► Artikel lesen
26.06.ALK Abello: First market launch of the adrenaline nasal spray, EURneffy, for treatment of adults and children in Germany259ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely...
► Artikel lesen
16.06.ALK Abello: ALK presented comprehensive data on two new paediatric AIT tablets and a nasal adrenaline spray at EAACI 2025199At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took place in Glasgow, Scotland, from 13 to 16 June 2025, the Danish pharmaceutical company ALK presented...
► Artikel lesen
08.05.ALK Abello: ITULATEK approved for treatment of children and adolescents in Canada305ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK's regulatory filing for ITULATEK® (tree pollen sublingual allergy immunotherapy tablet) for treatment of children and...
► Artikel lesen
06.05.ALK Abello: Three-month interim report (Q1) 2025 (unaudited)298ALK delivers 12% organic revenue growth with operating profit up 50% in Q1 Q1 results were strong as expected. Revenue increased on double-digit sales growth in all sales regions, including 22% growth...
► Artikel lesen
02.05.ARS Pharmaceuticals signs agreement with ALK-Abelló A/S for neffy4
02.05.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy (epinephrine nasal spray) to Additional U.S. Pediatricians1
29.04.ALK Abello: Invitation to the presentation of ALK's first quarter 2025 results on Tuesday, 6 May 20251
23.04.ALK Abello: ITULAZAX tree pollen tablet approved for treatment of children in Europe150ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged...
► Artikel lesen
03.04.ALK Abello: Grant of share-based long-term incentive instruments to members of the Board of Management and key employees1
13.03.ALK Abello: Annual General Meeting in ALK-Abelló A/S held on 13 March 20253
07.03.ALK Abello: ACARIZAX approved in Canada for treatment of young children425ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK's ACARIZAX® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX® is now indicated...
► Artikel lesen
04.03.ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff3
27.02.ALK Abello: FDA approves ODACTRA for the treatment of house dust mite allergy in young children371ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK's ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA®...
► Artikel lesen
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1